Massive data dive reveals how new prostate cancer drug performs in real patients
NCT ID NCT07450157
Summary
This study looked back at health records to understand how a newer prostate cancer drug, 177Lu-PSMA-617, was used in real-world practice. Researchers analyzed data from 6,448 patients to see who received the drug, how long they lived, and how their cancer markers changed. The goal was to gather knowledge about treatment patterns and outcomes after the drug became available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.